N/A
N=60
The Viability of Short Stems in Total Hip Arthroplasty
Osteoarthritis of Hip
Bottom Line
View on ClinicalTrials.gov: NCT02577822 ↗Enrolled (actual)
60
Serious AEs
—
Results posted
Aug 2019
Primary outcome: Primary: Mean VR-12 Mental Composite Score Through 2 Years Post Operative — 47.3; 50.6; 54.9; 53.8 T-Score
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Taperloc standard length stem (Device); Taperloc short length stem (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- Aug 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean VR-12 Mental Composite Score Through 2 Years Post Operative |
47.3; 50.6; 54.9; 53.8; 56.4; 56.9 | — |
| PRIMARY Mean VR-12 Physical Composite Score Through 2 Years Post Operative |
25.2; 23.6; 37.0; 37.8; 42.1; 40.1 | — |
| PRIMARY PROMIS Computerized Adaptive Tests (CATs) for Pain Behavior Through 2 Years Post-operative |
59.2; 61.3; 51.9; 51.0; 48.0; 52.0 | — |
| PRIMARY PROMIS Computerized Adaptive Tests (CATs) for Physical Function Through 2 Years Post-operative |
29.6; 31.7; 41.00; 42.6; 45.5; 45.4 | — |
| PRIMARY PROMIS Computerized Adaptive Tests (CATs) for Pain Interference Through 2 Years Post-operative |
64.6; 67.4; 51.7; 53.1; 49.7; 51.1 | — |
| SECONDARY EBRA (Ein-Bild-Roentgen-Analyse) Femoral Component Analysis (EBRA-FCA) of Implant Subsidence Through 2 Years Post Operative |
0.124; 0.193; 0.448; 0.702; 0.526; 1.303 | — |
Summary
The purpose of this study is to determine the viability of short femoral stems as an alternative to standard-length stems in total hip arthroplasty.
Eligibility Criteria
Inclusion Criteria
- Must require a total hip arthroplasty.
- Ages 18-85 years, regardless of gender, ethnicity, or pathology
Exclusion Criteria
- This study excludes any populations at risk.
- Minors, as well as any persons unable to consent, will not be eligible.
Data sourced from ClinicalTrials.gov (NCT02577822). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.